Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Novartis and NHS launch mobile eye unit in UK

First of its kind unit to offer 250 clinic slots per week across Surrey, Hampshire and Berkshire

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

- PMLiVE

Vertex will file combination cystic fibrosis therapy this year

Data supports use of lumacaftor alongside Kalydeco

National Institute for Health and Care Excellence NICE logo

NICE backs constipation treatment

Sucampo’s Amitiza set for NHS use in England and Wales

UK flag

NICE guidelines on atrial fibrillation discourage aspirin use

Health watchdog encourages greater NHS use of new anticoagulant drugs

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

National Institute for Health and Care Excellence NICE logo

NICE guidelines on statins will ‘medicalise’ the healthy, say doctors

Prominent physicians call for rethink on plans to lower treatment threshold

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

National Institute for Health and Care Excellence NICE logo

NICE denies Stelara’s use in psoriatic arthritis

Refuses to extend NHS-recommended indications of Janssen drug

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

- PMLiVE

Novartis appoints new comms chief

Michael Willi replaces Michele Galen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links